# Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.

> **NCT04311489** · PHASE2 · TERMINATED · sponsor: **University of Aarhus** · enrollment: 17 (actual)

## Conditions studied

- Cirrhosis, Liver
- Ascites Hepatic

## Interventions

- **DRUG:** Ularitide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04311489
- **Lead sponsor:** University of Aarhus
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-01
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-11-30
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Interim analysis showing safety concerns
- **Last updated:** 2023-05-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04311489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04311489, "Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04311489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*